Foghorn Therapeutics Inc. (FHTX)
NasdaqGM · USD · Healthcare · Biotechnology
$2.05 (+2.50%) as of
Key statistics
- Market cap
- 121.74M
- Forward P/E
- -2.00
- EPS (TTM)
- -0.9800
- Dividend yield
- 0.00%
- 52-week range
- 1.7900 – 7.6100
- Beta
- 3.01
- Revenue (TTM)
- 36.74M
- Profit margin
- -175.78%
- Analyst target
- $4.17
- Volume
- 509.69k
About Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Watertown, MA, United States
- Employees
- 106
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.